title: Vaccine safety.
abstract: Brief reports are presented on Swissmedic's experiences with PaniFlow, a tool to monitor Adverse Events Following Immunization (AEFI) of pandemic influenza (H1N1) 2009 vaccines and UMC's updates on AEFI of these vaccines; on WHO's Global Network for Post-marketing Surveillance of Prequalified Vaccines and India joining the network; the June 2010 meeting of the Global Advisory Committee on Vaccine Safety.
authors.affiliation: WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden. jerry.labadie@who-umc.org
authors.forename: Jerry
authors.initials: J
authors.lastname: Labadie
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D003257:Consumer Product Safety / Q000592:standards*; D006801:Humans; D007115:Immunization Schedule; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000592:standards; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control; D007391:International Cooperation; D020407:Internet; D058873:Pandemics; D011159:Population Surveillance; D014611:Vaccination / Q000009:adverse effects*
chemical_list: D007252:Influenza Vaccines